Erasca Inc (ERAS)
2.52
+0.04
(+1.61%)
USD |
NASDAQ |
May 31, 16:00
2.53
+0.01
(+0.40%)
Pre-Market: 20:00
Erasca Enterprise Value: 389.82M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 389.82M |
| May 30, 2024 | 378.90M |
| May 29, 2024 | 359.81M |
| May 28, 2024 | 389.82M |
| May 24, 2024 | 419.83M |
| May 23, 2024 | 408.91M |
| May 22, 2024 | 367.99M |
| May 21, 2024 | 343.44M |
| May 20, 2024 | 90.64M |
| May 17, 2024 | 43.83M |
| May 16, 2024 | 23.03M |
| May 15, 2024 | 29.96M |
| May 14, 2024 | 24.76M |
| May 13, 2024 | 31.70M |
| May 10, 2024 | 23.03M |
| May 09, 2024 | 42.10M |
| May 08, 2024 | 75.04M |
| May 07, 2024 | 80.24M |
| May 06, 2024 | 85.44M |
| May 03, 2024 | 73.30M |
| May 02, 2024 | 75.04M |
| May 01, 2024 | 64.64M |
| April 30, 2024 | 50.77M |
| April 29, 2024 | 55.97M |
| April 26, 2024 | 29.96M |
| Date | Value |
|---|---|
| April 25, 2024 | 28.23M |
| April 24, 2024 | 28.23M |
| April 23, 2024 | 36.86M |
| April 22, 2024 | 23.00M |
| April 19, 2024 | 12.60M |
| April 18, 2024 | 12.60M |
| April 17, 2024 | 21.26M |
| April 16, 2024 | 36.86M |
| April 15, 2024 | 49.00M |
| April 12, 2024 | 68.07M |
| April 11, 2024 | 99.27M |
| April 10, 2024 | 87.13M |
| April 09, 2024 | 94.07M |
| April 08, 2024 | 90.60M |
| April 05, 2024 | 66.33M |
| April 04, 2024 | 64.60M |
| April 03, 2024 | 78.47M |
| April 02, 2024 | 75.00M |
| April 01, 2024 | 29.55M |
| March 28, 2024 | -0.2719M |
| March 27, 2024 | -0.2719M |
| March 26, 2024 | -12.39M |
| March 25, 2024 | 1.243M |
| March 22, 2024 | 13.36M |
| March 21, 2024 | 13.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-59.41M
Minimum
Jan 31 2024
2.757B
Maximum
Sep 02 2021
550.29M
Average
265.50M
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 129.36B |
| Exelixis Inc | 5.355B |
| Geron Corp | 1.745B |
| Verastem Inc | 52.61M |
| Karyopharm Therapeutics Inc | 135.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.02M |
| Total Expenses (Quarterly) | 38.85M |
| EPS Diluted (Quarterly) | -0.23 |
| Earnings Yield | -32.94% |